The WifOR Institute has introduced a groundbreaking metric known as the ‘handprint’, designed to quantify the positive socioeconomic impact of pharmaceutical products. This innovative approach aims to provide a comprehensive sustainability metric that aligns with the industry’s increasing focus on environmental and social governance (ESG) criteria.
As the pharmaceutical sector faces mounting pressure to demonstrate its commitment to sustainability, the handprint metric offers a tangible way to measure and communicate the positive contributions of pharma products beyond traditional financial metrics. By integrating this new measure, companies can better articulate their value proposition to stakeholders, including investors and regulatory bodies, who are increasingly prioritizing sustainability in their decision-making processes.
The implications of adopting the handprint metric are significant. It not only enhances transparency but also encourages pharmaceutical companies to innovate in ways that promote both economic value and societal benefits. This dual focus could redefine competitive advantage in the sector, positioning companies that embrace this metric as leaders in the evolving landscape of sustainable healthcare.
Start your 7-day trial and see what the database can do →
